Rani Therapeutics Reports Third Quarter 2021 Financial Results, Provides Corporate Update
Rani Therapeutics Holdings, Inc. - Class A (RANI)
Company Research
Source: GlobeNewswire
SAN JOSE, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today reported financial results for the quarter ended September 30, 2021, and provided a corporate update. “I am pleased with the progress Rani has made since our IPO. As we build a solid foundation for being a successful public company, we are laser focused on creating value and achieving our milestones,” said Talat Imran, Chief Executive Officer of Rani Therapeutics. “Looking ahead, I’m excited about this important and exciting next phase as we prepare for additional clinical studies with the RaniPill™ capsule, including our Phase I study with Parathyroid Hormone planned for 2022.” Third Quarter 2021 and Subsequent Highlights Completed a GLP 7-day repeat oral administration study. In November 2021, Rani completed a GLP 7-day repeat oral administration study to e
Show less
Read more
Impact Snapshot
Event Time:
RANI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RANI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RANI alerts
High impacting Rani Therapeutics Holdings, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
RANI
News
- BGC, DRS and AMTX are among after hour movers [Seeking Alpha]Seeking Alpha
- Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $21.00 to $9.00. They now have a "buy" rating on the stock.MarketBeat
- Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) had its price target lowered by analysts at HC Wainwright from $16.00 to $12.00. They now have a "buy" rating on the stock.MarketBeat
- Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
RANI
Earnings
- 3/20/24 - Beat
RANI
Sec Filings
- 4/17/24 - Form ARS
- 4/17/24 - Form DEFA14A
- 4/17/24 - Form DEF
- RANI's page on the SEC website